Researchers developed a next-generation CAR-T therapy targeting the Eva1 antigen, overcoming historic barriers in treating solid tumors. By engineering enhanced receptor components, the therapy shows potent tumor-killing activity with promising implications for expanding the reach of CAR-T treatments beyond blood cancers.